

*National Institutes of Health
Office of Technology Transfer*



***Antibodies-related Technologies
Available for Licensing***

*National Institutes of Health (NIH) Office of Technology Transfer
6011 Executive Boulevard, Suite 325 • Rockville MD 20852-3804
Phone: 301-496-7057 • Website: www.ott.nih.gov*

INTRODUCTION

NIH has an extensive intellectual property portfolio of early-stage technologies¹ and also invests substantially in their development. Roughly 10 percent of the annual NIH budget is dedicated to intramural research and development activities -- resulting in inventions that form the basis of a variety of new medical technology and therapies in the areas of medical devices, software, vaccines, diagnostics, and reagents. Similar to university research, commercial partners are needed to make sure that the long hours at the lab bench and the public investment pay off in the end in marketed products.

NIH believes that innovative, early stage companies can play a significant role in the future development of leading-edge research. While the increasingly consolidated pharmaceutical industry remains a steady customer of research reagents and clinical collaborations with NIH, the more exciting therapeutic developments increasingly seem to come from NIH licenses signed with small and medium-sized life science companies early in their growth phase.

To further attract such early-stage concerns and start-ups, NIH affords creative treatment to small firms and tries to provide IP agreements that facilitate new areas of product development based upon NIH research. For example, financially-burdened smaller companies can benefit from flexibility on patent costs and license execution fees in license agreements. Of particular note for venture-backed firms is that companies do not give up equity or management control nor are their future development or marketing rights compromised by signing NIH license agreements. Finally, once the product is in development, NIH has the capability to assist with clinical trials, follow-on research collaborations, and even eventual purchase of the product as a customer.

We have collected some medical technologies your company might be interested in for further discussion with our licensing managers.

Once you have picked the technology of interest, we urge you to apply for a License. A copy of the License Application template can be found at the NIH OTT website at: http://www.ott.nih.gov/forms_model_agreements/forms_model_agreements.aspx

¹ *The NIH Office of Technology Transfer cannot guarantee that the listed technologies are still available for licensing. Please contact the Licensing and Patenting Manager (listed under each technology) for the current status and for other complementary technologies.*

Antibody

Ref No.	Title
E-058-2009	Development of a New Carbohydrate Antibody to GalNac1-3Gal
E-080-2008	Human and Improved Murine Monoclonal Antibodies Against CD22
E-079-2008	Human Monoclonal Antibody Against Mesothelin
E-084-1991	Antibodies and Polypeptides Specific to AAMP-1: Diagnostic and Therapeutic Uses Thereof
E-146-2007	Selenocysteine Mediated Hybrid Antibody Molecules
E-216-2009	High Diversity/High Affinity Domain Antibody Library
E-171-2009	Improved Antibodies Against ErbB4/Her4
E-053-2006	Polyclonal Antibody Against Bloom's Syndrome Protein (BLM) for Research and Diagnostic Use
E-274-2008	Monoclonal Antibodies to the Tumor-Specific Antigen, Human ROR1

E-003-2007	<u>Engineered Human Antibody Constant Domains (Nanoantibodies) as Scaffolds for Binders</u>
E-146-2007	<u>Selenocysteine Mediated Hybrid Antibody Molecules</u>
E-008-2010	<u>Phage Display Plasmids with Improved Expression Properties for Human and Chimeric Nonhuman/Human Fab Libraries</u>
E-274-2008	<u>Monoclonal Antibodies to the Tumor-Specific Antigen, Human ROR1</u>
E-211-2008	<u>Fully Human Anti-Human Monoclonal Antibody Helpful in Developing Therapies Against Autoimmune and Infectious Diseases and Cancer</u>
E-253-2008	<u>Polyclonal Antibodies to the Kidney Protein Sodium-Hydrogen Exchanger 3 (NHE3)</u>
E-254-2008	<u>Polyclonal Antibodies to Thiazide-Sensitive Sodium-Chloride Cotransporter (NCC)</u>
E-255-2008	<u>Polyclonal Antibodies to NKCC2, a Kidney-Specific Member of the Cation Chloride Co-transporter Family, SLC12A1</u>
E-268-2008	<u>Polyclonal Antibodies to the Kidney Protein Urea Transporter 1 (UTA1)</u>
E-323-2007	<u>Assay for Identification of Influenza-Neutralizing Antibodies</u>

E-125-2008	Monoclonal Antibodies That React With the Capsule of <i>Bacillus anthracis</i>
E-142-2008	Humanized Monoclonal Antibodies that Specifically Bind Japanese Encephalitis Virus (JEV) and Their Use
E-061-2009	Mouse Monoclonal Antibody Targeting Tetanus Toxin Heavy Chain Fragment C
E-211-2008	Fully Human Anti-Human Monoclonal Antibody Helpful in Developing Therapies Against Autoimmune and Infectious Diseases and Cancer
E-043-2008	Cross-Reactive Neutralizing Human Domain Antibody Against HIV-1
E-123-2007	Chimpanzee Monoclonal Antibodies That Neutralize Lethal And Edema Factors Of Anthrax Toxin
E-107-2004	Function-blocking Antibodies To The Lymphatic Endothelial Cell Specific Hyalonic Acid Receptor, LYVE-1
E-158-2004	Mouse Lactoferrin Antibody
E-131-2004	AT8, A Mouse Natural Killer Cell Receptor Specific Antibody
E-351-2004	Polyclonal Antibodies To The Ras-related Protein Rheb

E-090-2004	Nanotube/Monoclonal Antibody Cancer Therapy And Diagnostics
E-228-2006	Mouse Monoclonal Antibody To Mouse And Human MITF, A Cancer Related Transcription Factor
E-101-2006	Peptide Specific Antibodies To Human Asparagine Synthetase For L-asparaginase Cancer Therapy
E-217-2005	Human Monoclonal Antibodies That Specifically Bind IGF-II
E-336-2005	Human IGF-I Specific And IGF-I And IGF II Cross-reactive Human Monoclonal Antibodies
E-264-2005	Development Of A Polyclonal Antibody To Mouse Kai 1
E-168-2005	Monoclonal Antibody To The Protein NCOA6 (also Called ASC-2, AIB-3)
E-092-2004	Anti-Marinobufagenin Antibody (Clone 3EG) And Uses To Treat Hypertension, Pre-eclampsia, And Eclampsia
E-014-2004	Monoclonal Antibody MP804 And Its Detection Of Primitive Stem Cells In Adult Skeletal Muscle That Mature In Vitro Into Neuronal Cells
E-175-2006	Mouse Monoclonal Antibody (MBb) To The Nitron Spin Trap 5,5-dimethyl-1-pyrroline N-oxide (DMPO) For Use In Detection Of Stable Nitron End-products Of Specific Protein Radicals In Sandwich ELISA

E-020-2006	Isolation Of Human Anti-TLT-1 Antibody Fragments (single Chain Fvs) Recognizing Both Human And Murine TLT-1 Extracellular Domain
E-075-2006	Monoclonal Antibody To The Major Flagellin Protein (FLaB) Of Species Of The Bacterial Genus Borrelia. (Mab H9724)
E-180-2006	Neutralizing Mabs To Botulinum Neurotoxin A
E-297-2006	CCR5-specific Human Monoclonal Antibodies with Broad HIV-1 Neutralizing Activity
E-321-2004	Hepatitis C Virus Neutralizing Antibodies
E-137-2004	Reactivity Of Human Sera In A Sensitive, High-throughput Pseudovirus-based Papillomavirus Neutralization Assay For HPV16 And PHV18
E-144-2004	A Chimpanzee Monoclonal Antibody That Neutralizes Hepatitis B Virus
E-043-2000	Major Neutralization Site Of Hepatitis E Virus And Use Of This Neutralization Site In Methods Of Vaccination And In Methods Of Screening fr Neutralizing Antibodies to Hepatitis E Virus
E-017-2001	Monoclonal Antibodies Specific For The E2 Glycoprotein Of Hepatitis C Virus and Their Use In The Diagnosis, Treatment, and Prevention of Hepatitis C
E-145-2004	Monoclonal Antibodies Against Orthopoxviruses

E-146-2004	<u>Chimpanzee Monoclonal Antibody That Neutralizes Anthrax Protective Antigen (PA) Toxin</u>
E-123-2004	<u>Anti-vaccinia MAb</u>
E-015-2005	<u>New Antibodies To Mesothelin With High Affinity</u>
E-004-2004	<u>Anti-Plasmodium Antibodies And Methods Of Use</u>